Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2015-07-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
关于筹划重大事项的停牌公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the suspension of trading (停牌公告) due to the company planning a major matter. It states the stock will be suspended and that progress updates will be provided every five trading days. There is no financial data, no detailed report, no voting results, no management changes, no audit or earnings information. The document is an official regulatory announcement about trading suspension related to a major event planning. It is brief (476 characters) and serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2015-07-27 Chinese
关于全资子公司获得药品GMP证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its wholly-owned subsidiary receiving a pharmaceutical GMP certificate. It contains no financial data, no mention of financial results, no regulatory filings related to financial performance, and no indication of a report or meeting materials. It is a regulatory announcement about certification compliance. The document length is short (858 characters), and it is an announcement of a certification event rather than a financial or governance report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2015-07-22 Chinese
独立董事辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director from the company's board. It details the resignation, the reasons, and the implications for the board's composition, as well as the process for appointing a replacement. There is no financial data, no mention of financial results, no audit information, and no regulatory filings beyond the announcement itself. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2015-07-20 Chinese
2015年半年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2015年半年度业绩预告' which translates to '2015 Half-Year Performance Forecast'. It provides estimated financial results for the period January 1, 2015 to June 30, 2015, including expected net profit and earnings per share. It explicitly states that the forecast has not been audited and that detailed actual results will be disclosed in the 2015 half-year report. The document is a preliminary earnings forecast, not the actual interim report itself. It is also relatively short (683 characters). Therefore, this is an Earnings Release (ER) type document, as it announces key financial highlights for a period but does not contain full financial statements or detailed analysis. H1 2015
2015-07-14 Chinese
关于维护公司股价稳定方案的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement by 紫光古汉集团股份有限公司 regarding a plan to stabilize the company's stock price. It includes commitments by the largest shareholder not to reduce holdings and encouragement for directors and management to increase their holdings. There is no financial data, no mention of a report or meeting, and the document is short (511 characters). It is clearly an announcement related to capital market activity, specifically about shareholding and stock price stabilization measures. This fits best under 'Transaction in Own Shares' (POS) as it relates to shareholding actions and intentions by insiders and major shareholders to influence stock price stability.
2015-07-10 Chinese
关于股价异常波动公告的更正公告
Regulatory Filings Classification · 95% confidence The document is a correction announcement regarding a previously issued notice about abnormal stock price fluctuations. It clarifies that the price changes did not meet the exchange's criteria for abnormal fluctuations. The document is short (408 characters) and serves as a regulatory announcement correcting prior information. It does not contain financial statements, management changes, or detailed reports. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and corrections that do not fit other categories.
2015-06-15 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.